Clinical Trial

Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia

Study acronym: Inflamm-AML
Recruiting
View on ClinicalTrials.gov →
Summary
The study is designed as a collection of biological samples of newly diagnosed acute myeloid leukemia (AML) patients treated in the clinical units involved. Samples of peripheral blood (PB) and bone marrow (BM) will be analyzed to determine the Inflammasome profile before and after a first-line chemotherapy treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-08-01; most recent amendment 2026-06-04.
Status change: Not Yet Recruiting → Recruiting 2025-05-07
Trial Details
NCT Number NCT06535113
Lead Sponsor Ciceri Fabio
Collaborators: Azienda Ospedaliera Bianchi-Melacrino-Morelli
Conditions Acute Myeloid Leukemia
Enrollment 80 participants
Start Date 2025-02-22
Primary Completion 2026-05-11 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-08